ClariVest Asset Management’s Travere Therapeutics TVTX Stock Holding History

ClariVest Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-59,531	Closed	-$698K	–	617
2014 Q2	$698K	Buy	59,531 +20,234	+51%	+$274K	0.03%	256
2014 Q1	$837K	Buy	+39,297	New	+$604K	0.03%	233

Other funds holding TVTX

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

ClariVest Asset Management's TVTX Position: Q3 2014 in Review

ClariVest Asset Management sold out of Travere Therapeutics (TVTX) in Q3 2014, closing a stake of 59,531 shares — an estimated $698K sold.

ClariVest Asset Management first reported a position in TVTX in Q1 2014 and held it in 2 quarters. The position peaked at $837K in Q1 2014. 60 funds tracked by Wall St. Rank hold TVTX as of Q3 2014.

ClariVest Asset Management reported no remaining Travere Therapeutics position as of Q3 2014 after selling out during the quarter.
ClariVest Asset Management sold 59,531 Travere Therapeutics shares in Q3 2014, an estimated $698K.
ClariVest Asset Management first reported a position in Travere Therapeutics in Q1 2014 and held it in 2 quarters.
ClariVest Asset Management's Travere Therapeutics position peaked at $837K in Q1 2014.
60 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2014.

Based on ClariVest Asset Management's 13F filing for Q3 2014, filed 14 Oct 2014.